Arik Shahar - Innovid Corp VP Measurement
| CTV Stock | USD 3.05 0.04 1.33% |
Insider
Arik Shahar is VP Measurement of Innovid Corp
| Address | 30 Irving Place, New York, NY, United States, 10003 |
| Phone | 212 966 7555 |
| Web | https://www.innovid.com |
Innovid Corp Management Efficiency
The company has Return on Asset of (0.0257) % which means that on every $100 spent on assets, it lost $0.0257. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0702) %, meaning that it generated no profit with money invested by stockholders. Innovid Corp's management efficiency ratios could be used to measure how well Innovid Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2024. Return On Capital Employed is likely to drop to -0.08 in 2024. At this time, Innovid Corp's Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 106 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 74.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Leah Tate | Belden Inc | 47 | |
| Lisa Skelton | ADC Therapeutics SA | 53 | |
| Stephane Henchoz | ADC Therapeutics SA | N/A | |
| Amanda Hamilton | ADC Therapeutics SA | N/A | |
| Jacques Theurillat | ADC Therapeutics SA | 62 | |
| Kevin Maczka | Belden Inc | N/A | |
| Ronan Kelly | ADTRAN Inc | N/A | |
| Ashish Chand | Belden Inc | 49 | |
| Robert Schmidt | ADC Therapeutics SA | 43 | |
| Anshuman Mehrotra | Belden Inc | 53 | |
| Peter Greaney | ADC Therapeutics SA | 41 | |
| Maria Hedden | Comtech Telecommunications Corp | 54 | |
| Mitchell Walorski | CTS Corporation | N/A | |
| Michael Mulkerrin | ADC Therapeutics SA | 69 | |
| Thomas White | CTS Corporation | 38 | |
| Susan Romanus | ADC Therapeutics SA | 59 | |
| Yelena Simonyuk | Comtech Telecommunications Corp | N/A | |
| Richard Onyett | ADC Therapeutics SA | 73 | |
| Stephen Evansfreke | ADC Therapeutics SA | 68 | |
| Leo Kulmaczewski | Belden Inc | 58 | |
| Ye Li | CTS Corporation | 53 | |
Management Performance
| Return On Equity | -0.0702 | ||||
| Return On Asset | -0.0257 |
Innovid Corp Leadership Team
Elected by the shareholders, the Innovid Corp's board of directors comprises two types of representatives: Innovid Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innovid. The board's role is to monitor Innovid Corp's management team and ensure that shareholders' interests are well served. Innovid Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innovid Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tanya AndreevKaspin, Executive Officer | ||
| Tim Braz, VP Sales | ||
| Stephanie Geno, Chief Officer | ||
| Stephen Cook, General Counsel | ||
| Ken Markus, Chief Officer | ||
| John Williams, Head Relations | ||
| Pr Netter, CEO CoFounder | ||
| Michal Livny, Senior Operations | ||
| Anthony Callini, Chief Officer | ||
| Dani Cushion, Chief Officer | ||
| David Helmreich, Chief Officer | ||
| Kenneth Markus, Chief Officer | ||
| Liel Golan, Senior Resources | ||
| Yuval Pemper, Chief Officer | ||
| Tal Chalozin, CoFounder CTO | ||
| Arik Shahar, VP Measurement | ||
| Guy Kuperman, Chief Officer |
Innovid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Innovid Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0702 | ||||
| Return On Asset | -0.0257 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.04) % | ||||
| Current Valuation | 429.5 M | ||||
| Shares Outstanding | 148.47 M | ||||
| Shares Owned By Insiders | 13.21 % | ||||
| Shares Owned By Institutions | 55.92 % | ||||
| Number Of Shares Shorted | 1.31 M | ||||
| Price To Earning | 23.87 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Innovid Stock Analysis
When running Innovid Corp's price analysis, check to measure Innovid Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovid Corp is operating at the current time. Most of Innovid Corp's value examination focuses on studying past and present price action to predict the probability of Innovid Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovid Corp's price. Additionally, you may evaluate how the addition of Innovid Corp to your portfolios can decrease your overall portfolio volatility.